

PROGRESSIVE RETINAL ATROPHY – GR1

	REPORT NO.: SA2019/71518/0409/12
Client Name:	LIANE VAN DER HOVEN
Kennel Name:	
Client Address:	SUITE 69 PRIVATE BAG X16 7200
Client Tel No.:	072 697 0841
	
Canine Name:	BONYL MAGIC STAR
Breed:	GOLDEN RETRIEVER
Microchip No.:	945000001723550 Registration No.: ZA008974B17
Genetic Test:	PROGRESSIVE RETINAL ATROPHY – GR1
Result:	CLEAR

<h3>PROGRESSIVE RETINAL ATROPHY – GR1 (PRA_GR1)</h3> <p>Progressive Retinal Atrophy (PRA) is a collective of genetic eye disorders that share similar symptoms. There are numerous mutations that cause PRA in various canine breeds. PRA_GR1 is a late onset PRA discovered in Golden Retrievers responsible for 60% of PRA cases in Golden Retrievers.</p> <p>A single cytosine insertion at c.2601 in the SLC4A3 gene causes a shift in the reading frame and subsequent premature termination. PRA_GR1 is an autosomal recessive photoreceptor degenerative disease, where two copies of the mutation are required for an individual to be affected.</p> <p>Downs et al 2011. A Frameshift Mutation in Golden Retriever Dogs with Progressive Retinal Atrophy Endorses SLC4A3 as a Candidate gene for Human Retinal Degenerations. PLoS One 6(6), e21452.</p>	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">SAMPLE TYPE:</td> <td>EDTA BLOOD AMPULE</td> </tr> <tr> <td>EXTRACTION METHOD:</td> <td>DNA EXTRACTION</td> </tr> <tr> <td>TEST TYPE:</td> <td>SANGER SEQUENCE DETECTION</td> </tr> </table> <h3 style="text-align: center;">BREEDING IMPLICATIONS</h3> <table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th colspan="2" rowspan="2"></th> <th colspan="3">MATERNAL CANDIDATE</th> </tr> <tr> <th>CLEAR</th> <th>CARRIER</th> <th>AFFECTED</th> </tr> </thead> <tbody> <tr> <th rowspan="3" style="writing-mode: vertical-rl; transform: rotate(180deg);">PATERNAL CANDIDATE</th> <th>CLEAR</th> <td>ALL CLEAR</td> <td>50% CLEAR 50% CARRIER</td> <td>ALL CARRIER</td> </tr> <tr> <th>CARRIER</th> <td>50% CLEAR 50% CARRIER</td> <td>25% CLEAR 50% CARRIER 25% AFFECTED</td> <td>50% CARRIER 50% AFFECTED</td> </tr> <tr> <th>AFFECTED</th> <td>ALL CARRIER</td> <td>50% CARRIER 50% AFFECTED</td> <td>ALL AFFECTED</td> </tr> </tbody> </table> <p>Disclaimer: This report does not disregard the existence of any unknown or rare variant of SLC4A3 gene that may cause PRA, nor does it disregard the existence of any unknown or rare variant of any other gene that may cause or be associated with PRA in Golden Retrievers.</p>	SAMPLE TYPE:	EDTA BLOOD AMPULE	EXTRACTION METHOD:	DNA EXTRACTION	TEST TYPE:	SANGER SEQUENCE DETECTION			MATERNAL CANDIDATE			CLEAR	CARRIER	AFFECTED	PATERNAL CANDIDATE	CLEAR	ALL CLEAR	50% CLEAR 50% CARRIER	ALL CARRIER	CARRIER	50% CLEAR 50% CARRIER	25% CLEAR 50% CARRIER 25% AFFECTED	50% CARRIER 50% AFFECTED	AFFECTED	ALL CARRIER	50% CARRIER 50% AFFECTED	ALL AFFECTED
SAMPLE TYPE:	EDTA BLOOD AMPULE																											
EXTRACTION METHOD:	DNA EXTRACTION																											
TEST TYPE:	SANGER SEQUENCE DETECTION																											
		MATERNAL CANDIDATE																										
		CLEAR	CARRIER	AFFECTED																								
PATERNAL CANDIDATE	CLEAR	ALL CLEAR	50% CLEAR 50% CARRIER	ALL CARRIER																								
	CARRIER	50% CLEAR 50% CARRIER	25% CLEAR 50% CARRIER 25% AFFECTED	50% CARRIER 50% AFFECTED																								
	AFFECTED	ALL CARRIER	50% CARRIER 50% AFFECTED	ALL AFFECTED																								



DISCLAIMER: IT IS THE SENDER'S RESPONSIBILITY TO ENSURE THE CORRECTNESS OF INFORMATION ACCOMPANYING SAMPLE(S). INQABA BIOTEC™ WARRANTS THE TESTS TO BE ACCURATE FOR THE SAMPLE(S) OBTAINED FROM THE INDIVIDUALS IDENTIFIED IN THIS REPORT. IN NO EVENT SHALL INQABA BIOTEC™ BE HELD LIABLE FOR UNINTENDED, SUBSTANTIAL OR SECONDARY DAMAGES OF ANY KIND.